Orlando / Leverkusen / Mountain View / Naples / San Jose / /
Company
Bayer AG Inc. / Becton Dickinson / Creative Commons / Macmillan Publishers Limited / /
Continent
Europe / /
Country
Taiwan / Germany / Italy / United States / Vietnam / Korea / China / /
Currency
pence / / /
Event
FDA Phase / /
Facility
Second University of Naples / National Cancer Institute / Campus Bio-Medico / /
IndustryTerm
oxidative product / cancer therapy / permeabilization protocol / treatment of advanced hepatocellular cancer / treatment of cancer / important free radical scavenger systems / /
MedicalCondition
unresectable hepatocellular carcinoma / DF / Overall disease / primary liver cancer / advanced hepatocellular carcinoma / JE / HBV / human hepatoma cell HepG235 / neuroendocrine tumors / advanced hepatocellular cancer / unresectable and metastatic hepatocellular carcinoma / stationary disease / cirrhosis / human tumors / hepatitis C / J Cancer / hepatitis B / hepatocellular carcinomas / liver cirrhosis / liver disease / human breast cancer / breast cancer / tumor / human hepatoma cell HepG2 / common cancer / cancer / stationary diseases / tumors / Disease / cellular mitochondrial dysfunction / Cle´ries R. Primary liver cancer / human lung cancer / Cancer Hepatocellular carcinoma / hepatocellular carcinoma / Carcinogenesis / HCV / chronic liver diseases / portal hypertension / human hepatocellular carcinoma / Inflammation / N-nitrosodiethylamine-induced liver tumors / /
MedicalTreatment
cancer therapy / /
Organization
National Cancer Institute / Second University of Naples / Naples / Italy and 4University Campus Bio-Medico / Rome / 2Medical Oncology Unit / Ras Department of Biochemistry and Biophysics / Italian Association for Cancer Research / Department of Biochemistry and Biophysics / Second University of Naples / Naples / Italian Ministry for Education / European Union / /
Person
Wen-Sheng W. Protein / Ann Oncol / Ann N Y Acad Sci / / /
Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR